SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study
Completed
Bayer
Phase 3
2007-08-01
This study is conducted to compare the contrast effect and safety of SH L562BB with ProHance,
which has already been approved as a pharmaceutical product of similar indication.
Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain
Completed
Bracco Diagnostics, Inc
Phase 4
2012-08-01
This study aims at a direct comparison between ProHance (0.1 mmol/kg) and a validated
comparator Gadovist/Gadavist (0.1 mmol/kg) in a crossover intra-individual design in subjects
with brain tumors to confirm the identical overall technical and diagnostic performance of
the two MR contrast agents.
Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma
Completed
National Cancer Institute (NCI)
N/A
2015-01-06
This clinical trial studies steady state blood volume maps using ferumoxytol
non-stoichiometric magnetite magnetic resonance (MRI) in imaging patients with glioblastoma.
MRI is a procedure in which radio waves and a powerful magnet linked to a computer are used
to create detailed pictures of areas inside the body. Contrast agents, such as ferumoxytol
non-stoichiometric magnetite, may enhance these pictures and increase visibility of tumor
cells and the blood vessels in and around the tumors.
Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma
Completed
Oregon Health and Science University
N/A
2015-01-06
This clinical trial studies steady state blood volume maps using ferumoxytol
non-stoichiometric magnetite magnetic resonance (MRI) in imaging patients with glioblastoma.
MRI is a procedure in which radio waves and a powerful magnet linked to a computer are used
to create detailed pictures of areas inside the body. Contrast agents, such as ferumoxytol
non-stoichiometric magnetite, may enhance these pictures and increase visibility of tumor
cells and the blood vessels in and around the tumors.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
